

CITATION REPORT

List of articles citing

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

DOI: 10.1016/s0140-6736(03)12599-8
Lancet, The, 2003, 361, 653-61.

Source: <https://exaly.com/paper-pdf/35484963/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
743	Farmacotherapie bij unipolaire depressiefarmacotherapie stemmingsstoornissen Secondaryunipolaire. 2003 , 19, 356-368		
742	Hoelang antidepressiva gebruiken?. 2003 , 41, 138-138		
741	Current awareness in human psychopharmacology. 2003 , 18, 415-422		
740	Importance of language. <i>Lancet, The</i> , 2003 , 361, 1750	40	
739	Relapse prevention and antidepressants. <i>Lancet, The</i> , 2003 , 361, 2158; author reply 2159	40	1
738	Relapse prevention and antidepressants. <i>Lancet, The</i> , 2003 , 361, 2158-9; author reply 2159	40	
737	Opinion and Evidence in Neurology and Psychiatry. 2003 , 17, 363-370		
736	Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. 2003 , 17, 1109-17		33
735	Treatment of recurrent depression: an alternate viewpoint. 2003 , 17, 1119-22		1
734	'Real-life burden of depression' surveys--GP and patient perspectives on treatment and management of recurrent depression. 2003 , 19, 526-31		7
733	Death and dependence: current controversies over the selective serotonin reuptake inhibitors. 2003 , 17, 355-64		51
732	Better outcomes for depressive disorders?. <i>Psychological Medicine</i> , 2003 , 33, 769-74	6.9	15
731	Time to recurrence after recovery from major depressive episodes and its predictors. <i>Psychological Medicine</i> , 2003 , 33, 839-45	6.9	91
730	Clinical trials of antidepressant medications are producing meaningless results. <i>British Journal of Psychiatry</i> , 2003 , 183, 102-4	5.4	28
729	Conflict of interest in psychopharmacology: can Dr. Jekyll still control Mr. Hyde?. 2004 , 73, 1-4		14
728	Diagnosis and treatment of depression during pregnancy. 2004 , 9, 209-16		32
727	Is the Canadian health care system fiscally sustainable?. 2004 , 34, 229-43		1

726	Communicating evidence for participatory decision making. 2004 , 291, 2359-66	401
725	Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. 2004 , 38, 450-4	14
724	The burden of major depression avoidable by longer-term treatment strategies. 2004 , 61, 1097-103	149
723	Morbidity and mortality associated with pharmacotherapy. Evolution and current concept of drug-related problems. 2004 , 10, 3947-67	24
722	Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. 2004 , 38, 249-57	46
721	Evolutionary origins of depression: a review and reformulation. 2004 , 81, 91-102	112
720	Incidence and determinants of long-term use of antidepressants. 2004 , 60, 57-61	84
719	Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design. 2004 , 13, 176-83	5
718	The sequential approach to treating recurrent depression shows promise in some patients. 2004 , 20, 11-14	
717	Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. <i>British Journal of Psychiatry</i> , 2004 , 184, 393-403	5.4 236
716	Traitements antidépresseurs au long cours. 2004 , 1, 284-293	
715	[Evolution of depressive disorders]. 2004 , 33, 1469-73	
714	Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. 2004 , 161, 1537-47	396
713	One-year course of the first vs. multiple episodes of depression--Polish naturalistic study. 2004 , 19, 258-63	3
712	Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. 2004 , 161, 1877-84	35
711	Current World Literature. 2004 , 17, 53-74	
710	Traitements antidépresseurs au long cours. 2004 , 1, 1-6	
709	Relapse prevention with gepirone ER in outpatients with major depression. 2005 , 25, 79-84	18

708	The prognosis of depression in late life versus mid-life: implications for the treatment of older adults. 2005 , 17, 533-7	9
707	Relationship of Variability in Residual Symptoms With Recurrence of Major Depressive Disorder During Maintenance Treatment. 2005 , 3, 161-169	
706	Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. 2005 , 39, 683-692	8
705	The physician/investigator's obligation to patients participating in research: the case of placebo controlled trials. 2005 , 33, 575-85	11
704	Mitteilungen der DGPPN 11/05. 2005 , 76, 1432-1439	
703	Newer v. older antidepressants in long-term pharmacotherapy: Revisiting Prevention of relapse and recurrence of depression. 2005 , 11, 184-194	3
702	Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. 2005 , 73, 647-57	188
701	Bipolar depression in a low-income primary care clinic. 2005 , 162, 2146-51	48
700	Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. 2005 , 39, 683-92	69
699	Antidepressiva: Lebensgefährliche Plazebos? - Arznei-Telegramm: fahrlässiges Journal. 2005 , 31, 480-484	2
698	Depressive subtypes and efficacy of antidepressive pharmacotherapy. 2005 , 6 Suppl 2, 31-7	10
697	Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. 2005 , 162, 1805-19	451
696	New developments in antidepressant therapy. 2005 , 40, 95-105, vii	1
695	Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. 2005 , 6, 707-13	8
694	The medical management of depression. 2005 , 353, 1819-34	304
693	Antidepressant prevention of postnatal depression. 2005 , CD004363	25
692	Treatment of depression: time to consider folic acid and vitamin B12. 2005 , 19, 59-65	248
691	APRAND programme: an intervention to prevent relapses of anxiety and depressive disorders. First results of a medical health promotion intervention in a population of employees. 2006 , 21, 451-9	18

690	Relapse and recurrence in pediatric depression. 2006 , 15, 1057-79, xi		34
689	An evidence-based approach to the management of depression. 2006 , 33, 923-41, vii		3
688	Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. 2006 , CD003492		26
687	Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. 2006 , 75, 237-57		59
686	Open access: the evidence and the verdict. 2006 , 99, 435-436		1
685	International medical graduates. 2006 , 99, 436-436		
684	Depression: epidemic or pseudo-epidemic?. 2006 , 99, 436-436		
683	Preventing relapse and recurrence of depression: a brief review of therapeutic options. 2006 , 11, 12-21		60
682	Neuere kognitiv-verhaltenstherapeutische Ansätze zur Rückfallprävention bei rezidivierender Depression. 2006 , 16, 275-281		4
681	Trends in obesity: Authors' reply. 2006 , 99, 434-435		
680	Trends in obesity. 2006 , 99, 434-434		
679	Depression: epidemic or pseudo-epidemic?. 2006 , 99, 436		
678	Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. <i>British Journal of Psychiatry</i> , 2006 , 188, 346-53	5-4	67
677	Reasons for optimism not disillusionment. 2006 , 99, 435		2
676	Predictors of relapse in a prospective study of fluoxetine treatment of major depression. 2006 , 163, 1542-8		72
675	Model to assess the cost-effectiveness of new treatments for depression. 2006 , 22, 469-77		16
674	Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. 2006 , 26, 579-86		47
673	Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. 2006 , 21, 117-24		53

672	Withdrawing antidepressants: guide to patient management. 2006 , 17, 29-33	1
671	Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. 2006 , 256, 476-96	45
670	Translating effective depression care into practice: making an impact with IMPACT. 2006 , 28, 92-3	2
669	Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetrics practices. 2006 , 28, 289-95	95
668	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. 2006 , 110, 135-370	433
667	A biopsychosocial model as a guide for psychoeducation and treatment of depression. 2006 , 23, 312-24	102
666	Differential predictors of response to preventive cognitive therapy in recurrent depression: a 2-year prospective study. 2006 , 75, 229-36	52
665	Open access: the evidence and the verdict. 2006 , 99, 435-6	
664	Controversies in thromboprophylaxis for immobile patients secondary to neurological impairment. 2006 , 99, 436-7	
663	International medical graduates. 2006 , 99, 436	
662	Al-Razi and Islamic medicine in the 9th century. 2006 , 99, 437	2
661	Continuity of antidepressant treatment for adults with depression in the United States. 2006 , 163, 101-8	296
660	Six months of treatment for depression: outcome and predictors of the course of illness. 2006 , 163, 95-100	90
659	Are nonhuman primates good models for SARS?. 2006 , 3, e411; author reply e415	9
658	Authors' Response to Hockey and Reidak. 2006 , 3, e407	78
657	Authors' Response to Gowdy. 2006 , 3, e414	78
656	Authors' Response to Hogan. 2006 , 3, e415	78
655	Snakebite: sociocultural anthropological bias. 2006 , 3, e412	3

654	Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. 2006 , 63, 865-72	140
653	Is it just a marker for increased care?. 2006 , 3, e406; author reply e407	1
652	Were Eli Lilly unaware of this study?. 2006 , 3, e408; author reply e407	2
651	Crossing the language limitations. 2006 , 3, e410	
650	What guidelines? Never saw them!. 2006 , 3, e413; author reply e414	1
649	Rising mental health costs: what are we getting for our money?. 2006 , 25, 614-22	19
648	Relapse prevention in bipolar disorder: a critical review of current guidelines. 2006 , 20, 12-6	12
647	Doctors' strategies in prescribing drugs: the case of mood-modifying medicines. 2006 , 23, 73-9	4
646	The NICE Guidelines on the treatment of depression. 2006 , 15, 11-15	20
645	Helping to prioritise interventions for depression and schizophrenia: use of Population Impact Measures. 2006 , 2, 3	6
644	The risk of suicide with selective serotonin reuptake inhibitors in the elderly. 2006 , 163, 813-21	116
643	Treatment of recurrent depression. 2006 , 6, 1735-40	14
642	Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. 2007 , 164, 761-7	68
641	Antidepressant dose reduction and the risk of relapse in major depressive disorder. 2007 , 76, 266-70	21
640	Incremental change without policy learning: Explaining information rejection in English mental health services. 2007 , 9, 21-46	5
639	A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors. 2007 , 24, 570-5	49
638	Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication. 2007 , 64, 1196-203	103
637	Prevalence of depression diagnoses and use of antidepressant medications by veterans with spinal cord injury. 2007 , 86, 662-71	15

636	Impact of study design on the results of continuation studies of antidepressants. 2007 , 27, 177-81		14
635	Adherence to antidepressant treatment among privately insured patients diagnosed with depression. 2007 , 45, 363-9		112
634	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. 2007 , 10 Suppl 1, S1-207		37
633	High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. 2007 , 22 Suppl 2, S21-5		25
632	Enhanced treatment for depression in primary care: long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. <i>Psychological Medicine</i> , 2007 , 37, 849-62	6.9	46
631	Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. 2007 , 29, 691-702		30
630	Adherence to antidepressant treatment. 2007 , 7, 57-62		38
629	Prevention of depression: the state of the science at the beginning of the 21st Century. 2007 , 19, 655-70		44
628	Predictors of self-reported antidepressant adherence. 2007 , 32, 127-34		62
627	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. 2007 , 8, 67-104		249
626	Psychotherapy and antidepressant medication: Scope, procedure and interaction: A survey of psychotherapists' experience. 2007 , 9, 191-207		
625	[A strategy for therapy of depressive disorders and anxiety disorders by a health education intervention in medical consultations: the results of the APRAND program]. 2007 , 55, 113-21		
624	Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. 2007 , 27, 481-92		63
623	Continuation and maintenance treatments for depressive disorder in older adults. 2007 ,		3
622	Long-term treatment of depression with antidepressants: a systematic narrative review. 2007 , 52, 545-52		19
621	Depressive disorder needs an evidence base commensurate with its public health importance. 2007 , 52, 543-4		2
620	Early intervention for depressive disorders in young people: the opportunity and the (lack of) evidence. 2007 , 187, S15-7		37
619	Risk of Recurrence of Depression During Long-Term Antidepressant Treatment. 2007 , 12, 1-7		201

618	Definitions of recovery and outcomes of major depression: results from a 10-year follow-up. 2008 , 117, 35-40	25
617	Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. 2007 , 101, 57-63	68
616	Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. 2007 , 104, 251-61	13
615	Risk of adverse behavioral effects with pediatric use of antidepressants. 2007 , 191, 87-96	55
614	[Depressive disorders. A diagnostic and therapeutic challenge also for primary care]. 2007 , 48, 173-186; quiz 187-8	3
613	Rapid onset of true antidepressant action. 2007 , 9, 475-9	11
612	Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. 2008 , 258, 451-5	41
611	Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. 2008 , 258 Suppl 3, 3-23	64
610	Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?. 2008 , 3, 14	139
609	The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. 2008 , 23, 399-407	37
608	Acute and continuation therapy in unipolar depression: observations from the run-in phase of a maintenance trial. 2008 , 118, 123-9	3
607	The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. 2008 , 62, 623-32	14
606	Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. 2008 , 10, 957-68	98
605	Upping the ante on antidepressants. 2008 , 10, 975-8	3
604	The persistence of the placebo response in antidepressant clinical trials. 2008 , 42, 791-6	55
603	Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. 2008 , 178, 1293-301	40
602	Pharmacotherapy of mood disorders. 2008 , 4, 53-91	53
601	Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. 2008 , 76, 966-78	535

600	Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008 , 22, 343-96	341
599	Role of patient experience in antidepressant adherence: a retrospective data analysis. 2008 , 30, 1737-45	21
598	Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. 2008 , 18, 803-13	35
597	Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. 2008 , 172, 213-30	35
596	Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. 2008 , 9, 102-14	77
595	Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment. 2008 , 33, 320-31	286
594	Why does the world have such a 'down' on antidepressants?. 2008 , 22, 223-6	12
593	Addressing circadian rhythm disturbances in depressed patients. 2008 , 22, 13-8	14
592	Effects of Food and Drug Administration warnings on antidepressant use in a national sample. 2008 , 65, 94-101	124
591	Continuation and maintenance use of antidepressants in recurrent depression. 2008 , 77, 17-26	90
590	Adequacy of continuation and maintenance treatments for major depression in Japan. 2008 , 22, 153-6	5
589	Rückfallprophylaxe bei Depression. 2008 , 2, 73-87	2
588	Die Arzneimittelkommission der deutschen Ärzteschaft und Wirkstoff aktuell Venlafaxin in der Diskussion. 2008 , 34, 342-343	
587	Depression screening and patient outcomes in cardiovascular care: a systematic review. 2008 , 300, 2161-71	345
586	Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. 2008 , 149, 725-33	111
585	Interventions for preventing relapse and recurrence after the first episode of a depressive disorder in young people. 2008 ,	
584	Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants. 2008 , 59, 1121-1130	79
583	Room for improvement in the pharmacological treatment of anxiety disorders. 2008 , 14, 3482-91	15

582	Psychotherapy for depression: current empirical status and future directions. 507-515		1
581	A critical assessment of methods and processes used to develop psychiatric drug treatments. 47-56		
580	A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. 2008 , 50, 428-36		45
579	Randomized Trial of Weekly, Twice-Monthly, and Monthly Interpersonal Psychotherapy as Maintenance Treatment for Women With Recurrent Depression. 2008 , 6, 120-127		3
578	Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. 2008 , 23, 357-63		13
577	Psychopharmacology of mood disorders. 481-497		
576	The psychiatry of old age. 350-382		
575	Biological treatments of depression and anxiety. 622-635		
574	Psychiatric outcomes 10 years after treatment with antidepressants or anxiolytics. <i>British Journal of Psychiatry</i> , 2008 , 193, 327-31	5.4	10
573	Maintenance pharmacotherapy for recurrent major depressive disorder: 5-year follow-up study. <i>British Journal of Psychiatry</i> , 2008 , 193, 163-4	5.4	12
572	Recurrence rates in Ontario physicians monitored for major depression and bipolar disorder. 2009 , 54, 777-82		6
571	The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?. 2009 , 14, 5-12		6
570	Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. 2009 , 14, 8-14		14
569	Handbook of Depression. 2009 ,		
568	Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. 2009 , 66, 1304-12		142
567	Placebo effect in depression. 2009 , 166, 935		4
566	Potential limitations in generalizing findings from the TORDIA study. 2009 , 166, 935-6; author reply 936-7		
565	Biased public health perspective on depression treatment: media bias on publication bias. 2009 , 166, 934-5		2

564	Publication bias and the efficacy of antidepressants. 2009 , 166, 140-5	46
563	Evidence-based neurobehavioral electrophysiology. 2009 , 40, V	
562	Anticonvulsants in the treatment of major depressive disorder: an overview. 2009 , 17, 231-41	49
561	When to stop?. 2009 , 27, 1-3	3
560	Long-term effects of St. John's wort (<i>Hypericum perforatum</i>) treatment: a 1-year safety study in mild to moderate depression. 2009 , 16, 277-83	35
559	Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. 2009 , 115, 160-6	22
558	A systematic review of long-term studies of drug treated and non-drug treated depression. 2009 , 118, 9-18	48
557	Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. 2009 , 117 Suppl 1, S26-43	298
556	Relapse rates with long-term antidepressant drug therapy: a meta-analysis. 2009 , 24, 401-8	47
555	The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. 2009 , 24, 1325-32	69
554	Antidepressant adherence after psychiatric hospitalization among VA patients with depression. 2009 , 36, 406-15	13
553	[Core symptoms of depression]. 2009 , 80, 1371-6	
552	Persistence and compliance to antidepressant treatment in patients with depression: a chart review. 2009 , 9, 38	124
551	How many well vs. unwell days can you expect over 10 years, once you become depressed?. 2009 , 119, 290-7	9
550	Prevalence and predictors of recurrence of major depressive disorder in the adult population. 2010 , 122, 184-91	273
549	The health value and cost of care for major depression. 2009 , 12, 65-72	13
548	Review of choice and use of antidepressants. 2009 , 13, 14-20	8
547	Medicine taking behaviour in depression [part 1. 2009 , 13, 21-23	1

546	Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. 2009 , 81, 223-31	52
545	Psychopharmakologie. 2009 , 103-149	
544	The Maudsley Prescribing Guidelines. 2009 ,	110
543	Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. 2009 , 32, 1041-56	145
542	Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. 2009 , 10, 180-95	16
541	Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. 2009 , 104, 2897-902	45
540	Pharmacological treatment of generalized anxiety disorder. 2010 , 2, 453-67	20
539	Agomelatine: efficacy at each phase of antidepressant treatment. 2009 , 23 Suppl 2, 41-7	17
538	Does the length of the first antidepressant treatment episode influence risk and time to a second episode?. 2009 , 29, 69-72	18
537	Long-term outcome of anxiety disorders: a review of double-blind studies. 2009 , 22, 84-9	4
536	Frequent early discontinuation of SSRI prescribed by primary care physicians in young males in Japan. 2009 , 48, 1263-6	10
535	Factors impacting the selection of antidepressant treatment in patients with major depressive disorder at risk for nonadherence. 2009 , 14, 15-9	8
534	Psychotropic Medication Nonadherence Among United States Latinos: A Comprehensive Literature Review. 2009 , 60, 157-174	60
533	Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. 2010 , 30, 18-24	20
532	Six Months of Treatment for Depression: Outcome and Predictors of the Course of Illness. 2010 , 8, 286-293	
531	Forum: the use of selective serotonin reuptake inhibitors in depressed children and adolescents: commentary on the meta-analysis by Hetrick et al. 2010 , 23, 58-61	13
530	A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. 2010 , 25, 288-96	26
529	Effect of information leaflets and counselling on antidepressant adherence: open randomised controlled trial in a psychiatric hospital in Kuwait. 2010 , 13, 123-131	30

528	[Evidence-based therapy of depression: S3 guidelines on unipolar depression]. 2010 , 81, 1049-68	28
527	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. 2010 , 260, 145-50	27
526	Functional abdominal pain. 2010 , 12, 391-8	24
525	Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration. 2010 , 32, 2057-72	42
524	Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. 2010 , 123, 9-16	47
523	Study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the PREVENT trial. 2010 , 11, 99	29
522	Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. 2010 , 19, 1186-93	17
521	Continuation treatment of major depressive disorder: is there a case for duloxetine?. 2010 , 4, 19-31	11
520	Personality disorders predict relapse after remission from an episode of major depressive disorder: a 6-year prospective study. 2010 , 71, 1629-35	88
519	Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. 2010 , 33, 2611-6	136
518	Is the antidepressive effect of second-generation antidepressants a myth?. <i>Psychological Medicine</i> , 2010 , 40, 181-6	6.9 51
517	The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. 2010 , 24, 445-8	38
516	Illness risk following rapid versus gradual discontinuation of antidepressants. 2010 , 167, 934-41	72
515	Meta-analysis of relapse prevention antidepressant trials in depressive disorders. 2010 , 44, 697-705	57
514	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. 2010 , 13, 71-82	197
513	Efficacy and effectiveness of antidepressants: current status of research. 2010 , 79, 267-79	225
512	Unmasking special interest groups: the key to addressing conflicts of interest in medicine. 2010 , 79, 203-7	17
511	Does antidepressant step therapy fuel the law of unintended consequences?. 2010 , 167, 1148-51	1

510	Cost-effectiveness of improved primary care treatment of depression in women in Chile. <i>British Journal of Psychiatry</i> , 2010 , 197, 291-6	5.4	12
509	Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up. 2010 , 31, 355-77		46
508	The effect of an educational leaflet on depressive patients' attitudes toward treatment. 2010 , 177, 184-7		15
507	[Major depressive disorder: factors of risk, vulnerability and protection]. 2010 , 36 Suppl 5, S117-22		3
506	[Therapeutic strategy of depressive episodes. Prevention of relapse risk]. 2010 , 36 Suppl 5, S145-9		0
505	Self-rated residual symptoms do not predict 1-year recurrence of depression. 2010 , 25, 52-7		6
504	Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. 2010 , 25, 206-13		62
503	Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. 2010 , 20, 747-65		94
502	Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. 2010 , 24, 479-99		98
501	Guideline recommendations for long-term treatment of depression with antidepressants in primary care--a critical review. 2010 , 16, 106-12		36
500	Placebo and Antidepressant Treatment for Major Depression. 2010 , 62, 7-27		1
499	Centrally acting therapies for irritable bowel syndrome. 2011 , 40, 183-206		33
498	Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. 2011 , 19, 249-55		74
497	A critical review of pharmacotherapy for major depressive disorder. 2011 , 14, 1417-31		37
496	Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach. 2011 , 14, 492-8		12
495	Placebo, prozac and PLoS: significant lessons for psychopharmacology. 2011 , 25, 1277-88		36
494	Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. 2011 , 132 Suppl 1, S21-8		13
493	Down-regulation of serotonergic genes expression in the raphe nuclei of midbrain under chronic social defeat stress in male mice. 2011 ,		

492	Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. 2011 , 2, 159	59
491	Psychopharmacology in the Medical Setting. 2011 , 441-466	1
490	Modulating affect, cognition, and behavior - prospects of deep brain stimulation for treatment-resistant psychiatric disorders. 2011 , 5, 29	16
489	The effects of cognitive therapy versus 'treatment as usual' in patients with major depressive disorder. 2011 , 6, e22890	18
488	The effect of interpersonal psychotherapy and other psychodynamic therapies versus 'treatment as usual' in patients with major depressive disorder. 2011 , 6, e19044	9
487	Comparing antidepressant treatment patterns in older and younger adults: a claims database analysis. 2011 , 59, 1197-205	23
486	Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. 2011 , 65, 954-75	81
485	Mediating roles of adherence attitude and patient education on antidepressant use in patients with depression. 2011 , 47, 13-22	7
484	Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. 2011 , 45, 412-20	19
483	The association between antidepressant use and depression eight years later: a national cohort study. 2011 , 45, 1012-8	5
482	Rate of non-adherence prior to upward dose titration in previously stable antidepressant users. 2011 , 130, 46-52	11
481	The effects of continuous antidepressant treatment during the first 6 months on relapse or recurrence of depression. 2011 , 132, 121-9	23
480	Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. 2011 , 132 Suppl 1, S14-20	18
479	Depression: guide to detection and recommended management. 2011 , 22, 20-32	
478	Patients' attitudes toward side effects of antidepressants: an Internet survey. 2011 , 261, 103-9	18
477	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. 2011 , 261 Suppl 3, 207-45	29
476	[Considerations about the efficacy of psychopharmacological drugs]. 2011 , 82, 1425-30	4
475	The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?. 2011 , 13, 476-82	12

474	Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. 2011 , 12, 116	20
473	The effects of centralised and specialised combined pharmacological and psychological intervention compared with decentralised and non-specialised treatment in the early course of severe unipolar and bipolar affective disorders--design of two randomised clinical trials. 2011 , 12, 32	6
472	Should we treat depression with drugs or psychological interventions? A reply to Ioannidis. 2011 , 6, 8	8
471	The National Network of Depression Centers: progress through partnership. 2011 , 28, 615-21	8
470	[Antidepressants for mild depressive disorders]. 2011 , 38, 270-3	11
469	Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. 2011 , 44, 96-101	18
468	Duloxetine in the acute and continuation treatment of major depressive disorder. 2011 , 11, 1525-39	
467	Factors associated with recurrent depression: a prospective study in family practice. 2011 , 28, 22-8	14
466	STAR*D: A Tale and Trail of Bias. 2011 , 13, 6-28	19
465	Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. 2012 , 62, e773-9	42
464	Bonsai trees in your head: how the pavlovian system sculpts goal-directed choices by pruning decision trees. 2012 , 8, e1002410	217
463	The drugs don't work? antidepressants and the current and future pharmacological management of depression. 2012 , 2, 179-88	103
462	The use of Enhancing Quality Use of Medication Self-Reported Questionnaire (EQUIM-SRQ) among mental health consumers: a pilot study. 2012 , 20, 327-32	2
461	Are antidepressants useful in the treatment of minor depression: a critical update of the current literature. 2012 , 25, 1-6	12
460	Pharmacological treatment of unipolar depression. 2013 , 14, 263-89	5
459	Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior. 2012 , 2, e171	48
458	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012 , 200, 97-106	5-4 257
457	Does mindfulness based cognitive therapy prevent relapse of depression?. 2012 , 345, e7194	22

456	Recent Approaches to the Synthesis of Aripiprazole [A New Generation Antipsychotic Drug. 2012 , 9, 374-380		2
455	Continuation and maintenance treatments for depression in older people. 2012 , 11, CD006727		22
454	Effects of cognitive therapy versus interpersonal psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. <i>Psychological Medicine</i> , 2012 , 42, 1343-57	6.9	44
453	Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. 2012 , 12, 109-10		3
452	The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. 2012 , 27, 240-4		30
451	SAME and sexual functioning. 2012 , 27, 451-4		21
450	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. 2012 , 27, 114-28		27
449	[Integral Care Guide for Early Detection and Diagnosis of Depressive Episodes and Recurrent Depressive Disorder in Adults. Integral Attention of Adults with a Diagnosis of Depressive Episodes and Recurrent Depressive Disorder: Part II: General Aspects of Treatment, Management of the Acute Phase, Continuation and Maintenance of Patients with a Depression Diagnosis]. 2012 , 41, 740-73		2
448	Treatment selection in depression: the role of clinical judgment. 2012 , 35, 87-98		22
447	Meta-analyses and conflict of interest. 2012 , 26, 93-6		10
446	Studies of long-term use of antidepressants: how should the data from them be interpreted?. 2012 , 26, 97-109		27
445	The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice. 2012 , 10, 445-463		2
444	Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. 2012 , 11, CD007504		19
443	Relapses in recurrent depression 1 year after psychoeducational treatment: the role of therapist adherence and competence, and the therapeutic alliance. 2012 , 195, 51-5		7
442	The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase. 2012 , 13, 80		10
441	Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population. 2012 , 34, 571-7		11
440	Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand. 2012 , 15, S3-8		12
439	A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources. 2012 , 30, 461-82		23

438	A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. 2012 , 26, 1408-16	86
437	Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study. 2012 , 12, 125	36
436	Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial. 2012 , 12, 40	20
435	Evidence-based pharmacotherapy of major depressive disorder. 53-72	
434	Evidence-based pharmacotherapy of generalized anxiety disorder. 110-127	1
433	Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder. 2012 ,	
432	Psychopharmacology. 2012 , 585-615	1
431	How close is evidence to truth in evidence-based treatment of mental disorders?. 2012 , 262, 277-89	5
430	A proposed model for economic evaluations of major depressive disorder. 2012 , 13, 501-10	13
429	The effect of adding psychodynamic therapy to antidepressants in patients with major depressive disorder. A systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. 2012 , 137, 4-14	19
428	Can effects of antidepressants in patients with mild depression be considered as clinically significant?. 2012 , 138, 183-91	20
427	New users of antidepressant medications: first episode duration and predictors of discontinuation. 2012 , 68, 65-71	25
426	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. 2012 , 262, 13-22	17
425	Role of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice. 2013 , 1, 41-49	37
424	Behavioral Neurobiology of Depression and Its Treatment. 2013 ,	3
423	The Implementation of Mindfulness-Based Cognitive Therapy: Learning From the UK Health Service Experience. 2013 , 4, 246-254	73
422	Multidimensional health locus of control and depressive symptoms in the multi-ethnic population of the Netherlands. 2013 , 48, 1931-9	13
421	Health care providers' perspectives of medication adherence in the treatment of depression: a qualitative study. 2013 , 48, 1657-66	8

420	Mental disorders as "brain diseases" and Jaspers' legacy. 2013 , 12, 1-3	18
419	One ring to rule them all?--Temporospatial specificity of deep brain stimulation for treatment-resistant depression. 2013 , 81, 611-8	5
418	Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited. 2013 , 5, 219-30	9
417	Hauptsache Berhaupt erstmal behandeln. 2013 , 15, 10-11	
416	Review of the choice and use of antidepressant drugs. 2013 , 17, 18-26	13
415	A randomized-controlled trial of an intervention to improve antidepressant adherence among Latinos with depression. 2013 , 30, 688-96	25
414	The failure of the antidepressant drug discovery process is systemic. 2013 , 27, 407-13; discussion 413-6	38
413	The DSM-5 debate over the bereavement exclusion: psychiatric diagnosis and the future of empirically supported treatment. 2013 , 33, 825-45	68
412	Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5). 2013 , 148, 286-90	8
411	Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: a randomized controlled superiority trial. 2013 , 23, 1057-66	31
410	Prescription patterns following first-line new generation antidepressants for depression in Japan: a naturalistic cohort study based on a large claims database. 2013 , 150, 916-22	15
409	Antidepressants from a public health perspective: re-examining effectiveness, suicide, and carcinogenicity. 2013 , 127, 89-93	9
408	Downregulation of serotonergic gene expression in the Raphe nuclei of the midbrain under chronic social defeat stress in male mice. 2013 , 48, 13-21	52
407	Are antidepressants overprescribed? Yes. 2013 , 346, f191	33
406	Continuation transcranial direct current stimulation for the prevention of relapse in major depression. 2013 , 144, 274-8	62
405	Talking Controversy: Long-Term Users of Antidepressants and the Diagnosis of Depression. 2013 , 10, 428-444	1
404	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. 2013 , 14, 334-85	346
403	Prefrontal cortex function in remitted major depressive disorder. <i>Psychological Medicine</i> , 2013 , 43, 1219-30	25

402	Motivational pharmacotherapy: combining motivational interviewing and antidepressant therapy to improve treatment adherence. 2013 , 76, 203-9		22
401	Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. 2013 , 17, 35-43		7
400	Adherence to antidepressants. 2013 , 4, 44		1
399	Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. 2013 , 28, 20-8		13
398	A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. 2013 , 28, 206-13		2
397	Recurrence of major depressive disorder and its predictors in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). <i>Psychological Medicine</i> , 2013 , 43, 39-48	6.9	104
396	When does depression become a disorder? Using recurrence rates to evaluate the validity of proposed changes in major depression diagnostic thresholds. 2013 , 12, 44-52		83
395	Pharmacological management of unipolar depression. 2013 , 127, 6-23		28
394	Continuity of outpatient treatment after discharge of patients with major depressive disorder. 2013 , 201, 519-24		2
393	Adherence to antidepressant medications: an evaluation of community pharmacists' counseling practices. 2013 , 7, 813-25		27
392	Management of adult major depressive disorder. 37-58		
391	Modeling the dynamics of disease states in depression. 2014 , 9, e110358		8
390	New roles for pharmacists in community mental health care: a narrative review. <i>International Journal of Environmental Research and Public Health</i> , 2014 , 11, 10967-90	4.6	97
389	Antidepressants in primary care: patients' experiences, perceptions, self-efficacy beliefs, and nonadherence. 2014 , 8, 179-90		10
388	Chronic and treatment resistant depression: diagnosis and stepwise therapy. 2014 , 111, 766-75; quiz 775		36
387	Levomilnacipran: a newly approved drug for treatment of major depressive disorder. 2014 , 7, 137-45		18
386	Adverse effects of antidepressants during pregnancy. 2014 , 17, 103-4		
385	Pharmacotherapy of postpartum depression: an update. 2014 , 15, 1223-34		45

384	Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013. 2014 , 31, 755-68		18
383	Empirically supported methods of short-term psychodynamic therapy in depression - towards an evidence-based unified protocol. 2014 , 169, 128-43		50
382	Depression monitoring and patient behavior in the Clinical Outcomes in MEasurement-Based Treatment (COMET) trial. 2014 , 65, 1058-61		5
381	A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. 2014 , 15, 2525-42		33
380	The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. 2014 , 171, 1067-73		136
379	Predictive validation of single-episode uncomplicated depression as a benign subtype of unipolar major depression. 2014 , 129, 445-57		48
378	The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression. 2014 , 14, 324		25
377	Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. 2014 , 29, 36-44		46
376	Primary-care patients' trade-off preferences with regard to antidepressants. <i>Psychological Medicine</i> , 2014 , 44, 2301-8	6.9	10
375	Adherence of antidepressants during pregnancy: MEMS compared with three other methods. 2014 , 4, 61-9		11
374	Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer. <i>Psychological Medicine</i> , 2014 , 44, 1451-60	6.9	26
373	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. 2014 , 264, 567-75		31
372	Noncontinuous use of antidepressant in adults with major depressive disorders - a retrospective cohort study. 2014 , 4, 390-7		15
371	Potential long-term effects of a mind-body intervention for women with major depressive disorder: sustained mental health improvements with a pilot yoga intervention. 2014 , 28, 377-83		40
370	Effect van maternaal clomipraminegebruik op de neonaat: mild tot ernstig. 2014 , 82, 117-121		1
369	Attacks on antidepressants: signs of deep-seated stigma?. 2014 , 1, 102-4		21
368	Drug approval and drug effectiveness. 2014 , 10, 741-66		16
367	Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. 2014 , 70, 89-98		48

366	Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. 2014 , 23, 973-92	65
365	Current Status of Lithium in the Treatment of Mood Disorders. 2014 , 1, 294-305	5
364	The effects of acute treatment with paroxetine, amitriptyline, and placebo on the equilibrium function in healthy subjects: a double-blind crossover trial. 2014 , 18, 32-6	1
363	Pharmacist-patient communication on use of antidepressants: a simulated patient study in community pharmacy. 2014 , 10, 419-37	34
362	Handbook of Depression. 2014 ,	1
361	Long-term antidepressant treatment: time for a review?. 2015 , 26, 7-10	9
360	Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder. 2015 , 902-965	
359	Psychobiological Processes and Therapies in Depression. 2015 , 81-113	
358	Stimulants. 2015 , 2205-2235	
357	Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance. 2015 , 15, 1184	16
356	Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. 2015 , 10, 49-62	15
355	Effect of a Multi-Dimensional and Inter-Sectoral Intervention on the Adherence of Psychiatric Patients. 2015 , 10, e0139302	4
354	. 2015 ,	5
353	State-dependent and trait-related gray matter changes in nonrefractory depression. 2015 , 26, 57-65	15
352	Encyclopedia of Psychopharmacology. 2015 , 11-18	
351	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. 2015 , 29, 459-525	381
350	Antidepressant self-discontinuation: results from the collaborative psychiatric epidemiology surveys. 2015 , 66, 455-62	24
349	Antidepressants versus placebo in major depression: an overview. 2015 , 14, 294-300	93

348	Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. 2015 , 15, 121-129		35
347	Adherence to antidepressant therapy and mortality rates in ischaemic heart disease: cohort study. <i>British Journal of Psychiatry</i> , 2015 , 206, 297-301	5-4	18
346	The Risk of Switch to Mania in Patients With Bipolar Disorder During Treatment With an Antidepressant Alone and in Combination With a Mood Stabilizer. 2015 , 13, 68-74		
345	The Wakley Prize, 2015: what do you know?. <i>Lancet, The</i> , 2015 , 386, 12	40	2
344	Persistent decrease in alpha current density in fully remitted subjects with major depressive disorder treated with fluoxetine: A prospective electric tomography study. 2015 , 96, 191-200		3
343	Enduring effects of Preventive Cognitive Therapy in adults remitted from recurrent depression: A 10 year follow-up of a randomized controlled trial. 2015 , 185, 188-94		20
342	The impact of age and gender on adherence to antidepressants: a 4-year population-based cohort study. 2015 , 232, 3385-90		26
341	Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 63-73	40	278
340	Explaining the variation between practices in the duration of new antidepressant treatment: a database cohort study in primary care. 2015 , 65, e114-20		6
339	Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. 2015 , 39, 58-70		63
338	Depression relapse: importance of a long-term perspective. <i>Lancet, The</i> , 2015 , 386, 10-12	40	5
337	Toward a cultural adaptation of pharmacotherapy: Latino views of depression and antidepressant therapy. 2015 , 52, 244-73		34
336	A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. 2015 , 41, 16-26		149
335	Duration of initial antidepressant treatment and subsequent relapse of major depression. 2015 , 35, 75-6		33
334	Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up. 2015 , 225, 680-6		12
333	Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and meta-regression. 2015 , 174, 400-10		106
332	Biosynthesis, characterization and antibacterial effect of plant-mediated silver nanoparticles using <i>Ceropegia thwaitesii</i> [An endemic species]. 2015 , 63, 119-124		92
331	Interventions for preventing relapse or recurrence of depression in primary health care settings: A systematic review. 2015 , 76 Suppl, S16-21		9

330	An adaptationist perspective on the etiology of depression. 2015 , 172, 315-23	84
329	Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People's Republic of China. 2016 , 12, 941-9	8
328	A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research. 2016 , 2016, 7909176	4
327	Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials. 2016 , 10, 3899-3907	6
326	Psychotherapy Versus Pharmacotherapy of Depression: What's the Evidence?. 2016 , 62, 190-5	9
325	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. 2016 , 14, 191-9	12
324	Long-term antidepressant use: patient perspectives of benefits and adverse effects. 2016 , 10, 1401-7	72
323	ANTIDEPRESSANT ADHERENCE ACROSS DIVERSE POPULATIONS AND HEALTHCARE SETTINGS. 2016 , 33, 765-74	31
322	The Rise of Primary Care Physicians in the Provision of US Mental Health Care. 2016 , 41, 559-83	26
321	Bad Medicine: The rise and rise of antidepressants. 2016 , 66, 573	2
320	Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study. 2016 , 6, e009510	23
319	Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder. 2016 , 85, 171-9	61
318	Beliefs about antidepressant medication and associated adherence among older Chinese patients with major depression: A cross-sectional survey. 2016 , 25, 71-9	12
317	Continuation and maintenance treatments for depression in older people. 2016 , 9, CD006727	45
316	Understanding in vivo modelling of depression in non-human animals: a systematic review protocol. 2016 , 3, e00024	4
315	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. 2016 , 16, 153	6
314	Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England. 2016 , 16, 346	14
313	Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). 2016 , 2, 38	3

312	Identifying and describing patient perspectives on long-term antidepressant use. 2016 , 3, 1223902	1
311	THE LONG-TERM EFFICACY OF ACUTE-PHASE PSYCHOTHERAPY FOR DEPRESSION: A META-ANALYSIS OF RANDOMIZED TRIALS. 2016 , 33, 370-83	28
310	Depression Screening, Diagnosis, and Treatment Across the Lifespan. 2016 , 43, 229-43	2
309	A longitudinal study of educational differences in antidepressant use before and after hospital care for depression. 2016 , 26, 1034-1039	3
308	Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. 2016 , 31, 504-13	23
307	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. 2016 , 30, 495-553	468
306	Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. 2016 , 16, 367-74	22
305	Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. 2016 , 194, 144-52	100
304	Treatment of Bipolar Depression: Evolving Recommendations. 2016 , 39, 11-33	22
303	Brain-gut-microbiota axis: challenges for translation in psychiatry. 2016 , 26, 366-72	120
302	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health. 2016 , 3, 436-42	10
301	Vortioxetine: a New Treatment for Major Depressive Disorder. 2016 , 17, 421-31	43
300	Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. 2015 , 19,	84
299	[Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care]. 2016 , 48, 308-15	4
298	Playing With Antidepressants: Perspectives From Indian Australians and Anglo-Australians Living With Depression. 2017 , 27, 1970-1981	6
297	Predicting relapse after antidepressant withdrawal - a systematic review. <i>Psychological Medicine</i> , 2017 , 47, 426-437	6.9 39
296	Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. 2017 , 4, 230-237	30
295	[A computerised clinical decision-support system for the management of depression in Primary Care]. 2017 , 49, 359-367	4

294	Meta-Analysis of the Risk of Subsequent Mood Episodes in Bipolar Disorder. 2017 , 86, 90-98	40
293	Catalytic reduction of 4-nitrophenol and photo inhibition of <i>Pseudomonas aeruginosa</i> using gold nanoparticles as photocatalyst. 2017 , 170, 181-187	17
292	Mental health service use and need for care of Australians without diagnoses of mental disorders: findings from a large epidemiological survey. 2017 , 26, 596-606	10
291	Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. 2017 , 26, 676-684	4
290	The ten-year course of depression in primary care and long-term effects of psychoeducation, psychiatric consultation and cognitive behavioral therapy. 2017 , 217, 174-182	12
289	Maintenance efficacy designs in psychiatry: Randomized discontinuation trials - enriched but not better. 2017 , 1, 198-204	9
288	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. <i>British Journal of Psychiatry</i> , 2017 , 211, 127-129	5-4 24
287	Differential failure to deactivate the default mode network in unipolar and bipolar depression. 2017 , 19, 386-395	25
286	Internet- and mobile-based aftercare and follow-up for mental disorders: protocol of a systematic review and meta-analysis. 2017 , 7, e016696	2
285	Differing antidepressant maintenance methodologies. 2017 , 61, 87-95	7
284	Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients. 2017 , 43, 92-96	13
283	Effectiveness of Supported Self-Help in Recurrent Depression: A Randomized Controlled Trial in Primary Care. 2017 , 86, 220-230	16
282	Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands. 2017 , 86, 362-369	21
281	Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix) to Guide Treatment of Patients with Depression and/or Anxiety. 2017 , 35, 1297-1310	5
280	Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI). 2017 , 20, 28-41	4
279	Use of a self-rating scale to monitor depression severity in recurrent GP consultations in primary care - does it really make a difference? A randomised controlled study. 2017 , 18, 6	11
278	Biological synthesis and antimicrobial activity of nano silver using <i>Hypericum scabrum</i> seed extract. 2017 , 47, 870-875	2
277	Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. 2017 , 208, 6-14	28

276	Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm. 2017 , 8, 275	25
275	Antibacterial Activity and Synergistic Antibacterial Potential of Biosynthesized Silver Nanoparticles against Foodborne Pathogenic Bacteria along with its Anticandidal and Antioxidant Effects. 2017 , 8, 167	171
274	Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. 2017 , 13, 2151-2165	32
273	Driving performance of stable outpatients with depression undergoing real-world treatment. 2018 , 72, 399-408	8
272	Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. 2018 , 5, 401-410	48
271	Recurrence and chronicity of major depressive disorder and their risk indicators in a population cohort. 2018 , 137, 503-515	42
270	Time to rethink the approach to recurrent depression. 2018 , 5, 380-381	2
269	Relapse/Recurrence Prevention in Major Depressive Disorder: 26-Month Follow-Up of Mindfulness-Based Cognitive Therapy Versus an Active Control. 2018 , 49, 836-849	14
268	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. 2018 , 154, 1140-1171.e1	155
267	Utilizing Education and Perspective Taking to Remediate the Stigma of Taking Antidepressants. 2018 , 54, 450-459	7
266	Antidepressants for preventing postnatal depression. 2018 , 4, CD004363	19
265	Antidepressant Use by Class: Association with Major Adverse Cardiac Events in Patients with Coronary Artery Disease. 2018 , 87, 85-94	18
264	Choline and N-acetyl aspartate levels in the dorsolateral prefrontal cortex at the beginning of the recovery phase as markers of increased risk for depressive episode recurrence under different duration of maintenance therapy and after it: a retrospective cohort study. 2018 , 59, 244-252	2
263	The conundrum of depression clinical trials: one size does not fit all. 2018 , 33, 239-248	16
262	Legacy Drug-Prescribing Patterns in Primary Care. 2018 , 16, 515-520	15
261	Management of Late-Life Depression. 2019 , 250, 389-413	3
260	Internet- and mobile-based aftercare and relapse prevention in mental disorders: A systematic review and recommendations for future research. 2018 , 14, 1-17	28
259	Course of major depressive disorder after pregnancy and the postpartum period. 2018 , 35, 1130-1136	5

258	Improving Depression Outcome by Patient-Centered Medical Management. 2018 , 175, 1187-1198	18
257	Antidepressants and recurrence of depression in the postpartum period. 2018 , 21, 821-828	1
256	Depression, Anxiety, and Stress. 2018 , 391-411	
255	Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. 2018 , 24, 726-734	14
254	Eye Movement Desensitization and Reprocessing Versus Treatment as Usual in the Treatment of Depression: A Randomized-Controlled Trial. 2018 , 9, 1384	14
253	Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review. 2018 , 87, 268-275	10
252	The effect of CBT and its modifications for relapse prevention in major depressive disorder: a systematic review and meta-analysis. 2018 , 18, 50	37
251	Predictors of Depressive Relapse in Women Undergoing Infertility Treatment. 2018 , 27, 1408-1414	5
250	Dropouts in an Antidepressant Trial: How Do They Fare Afterwards?. 2018 , 87, 380-382	1
249	Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience. 2018 , 87, 257-267	36
248	Increasing Restlessness Signals Impending Increase in Depressive Symptoms More than 2 Months before It Happens in Individual Patients. 2019 , 88, 249-251	10
247	Pharmacological and non-pharmacological interventions of depression after traumatic brain injury: A systematic review. 2019 , 865, 172775	8
246	Comparison of surf and hike therapy for active duty service members with major depressive disorder: Study protocol for a randomized controlled trial of novel interventions in a naturalistic setting. 2019 , 16, 100435	1
245	The epidemiology of antidepressant use in South Korea: Does short-term antidepressant use affect the relapse and recurrence of depressive episodes?. 2019 , 14, e0222791	3
244	Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. 2019 , 6, 935-950	35
243	Managing Antidepressant Discontinuation: A Systematic Review. 2019 , 17, 52-60	33
242	Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. 2019 , 36, 225-234	4
241	Antidepressive Effects of Taraxacum Officinale in a Mouse Model of Depression Are Due to Inhibition of Corticosterone Levels and Modulation of Mitogen-Activated Protein Kinase Phosphatase-1 (Mkp-1) and Brain-Derived Neurotrophic Factor (Bdnf) Expression. 2019 , 25, 389-394	5

240	Treatment-Resistant Depression Among US Military Veterans. 2019 , 93-112	1
239	A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpReSSion): study protocol for a randomised controlled trial. 2019 , 20, 319	7
238	Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. 2019 , 9, e027574	15
237	Guidelines for the diagnosis and treatment of depressive disorders in China: The second edition. 2019 , 253, 352-356	4
236	Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy: A Randomized Controlled Pilot Trial. 2019 , 35, 115-121	7
235	Predicting relapse in major depression after successful initial pharmacological treatment. 2019 , 250, 108-113	8
234	Antidepressants; what's the beef?. 2019 , 31, 59-60	7
233	Depression in primary care: part 2-management. 2019 , 365, l835	19
232	Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. 2019 , 59, 834-847	20
231	Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants. 2019 , 5, e12	2
230	Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: a modelling study. 2019 , 22, 145-152	3
229	Nieuw onderzoek naar de afbouw van antidepressiva. 2019 , 62, 63-63	1
228	Non-adherence to antidepressants among older patients with depression: a longitudinal cohort study in primary care. 2019 , 36, 12-20	8
227	Synthesis of Gossypium hirsutum-derived silver nanoparticles and their antibacterial efficacy against plant pathogens. 2019 , 33, e4630	44
226	Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder. 2019 , 245, 403-411	3
225	Definition and Epidemiology of Treatment Resistance in Psychiatry. 2019 , 3-24	1
224	Should antidepressants be used for major depressive disorder?. 2020 , 25, 130	35
223	Managing Depression with Herbal Formula: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2020 , 26, 8-24	9

222	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. 2020 , 131, 91-101		16
221	When to consider electroconvulsive therapy (ECT). 2020 , 141, 304-315		36
220	The antidepressant standoff: why it continues and how to resolve it. <i>Psychological Medicine</i> , 2020 , 50, 177-186	6.9	6
219	Effect of acute citalopram on self-referential emotional processing and social cognition in healthy volunteers. 2020 , 6, e124		3
218	May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. 2020 , 10, 2045125320970325		13
217	Barriers to discontinuing antidepressants in patients with depressive and anxiety disorders: a review of the literature and clinical recommendations. 2020 , 10, 2045125320933404		1
216	Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. 2020 , 24, 341-348		4
215	Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. 2020 , 40, 1009-1020		3
214	The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. 2020 , 10, 2045125320967183		19
213	The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse. <i>Scientific Reports</i> , 2020 , 10, 22346	4.9	4
212	Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research. 2020 , 10, 2045125320964097		2
211	Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. 2020 , 16, 2943-2959		3
210	How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. 2020 , 10, 2045125320921694		21
209	Good Clinical Practice in Psychopharmacology. 2020 , 203-203		
208	Drugs to Treat Depression. 2020 , 227-267		
207	A Computational Theory of Mindfulness Based Cognitive Therapy from the "Bayesian Brain" Perspective. 2020 , 11, 404		6
206	Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	2
205	Effectiveness of mindfulness-based cognitive therapy on the management of depressive disorder: Systematic review. 2020 , 12, 100200		4

204	A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. 2020 , 266, 173-181	2
203	Computational Mechanisms of Effort and Reward Decisions in Patients With Depression and Their Association With Relapse After Antidepressant Discontinuation. 2020 , 77, 513-522	21
202	Antidepressants in inflammatory bowel disease. 2020 , 17, 184-192	23
201	Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults. 2020 ,	1
200	Let's talk about depression: social workers' use of chemical imbalance explanations. 2020 , 18, 237-256	2
199	Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. 2020 , 21, 521-531	9
198	Strategies to reduce use of antidepressants. 2021 , 87, 23-33	8
197	Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report. 2021 , 38, 185-195	3
196	Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA. 2021 , 11, 20451253211032051	3
195	Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. 2021 , 1-19	
194	Combined Cognitive-Behavioral Therapy and Placebo Treatment for Patients with Depression: A Follow-Up Assessment. 2021 , 14, 233-238	1
193	Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. 2021 , 4, CD013495	12
192	Perceived helpfulness of depression treatments among young adults with autism. 2021 , 14, 1522-1528	0
191	Deprescribing Antidepressants in Older People - Breaking Up Can Be Hard to Do. 2021 , 36, 228-237	0
190	Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study. 2021 , 5,	6
189	The Effects of Ibuprofen Consumption on the Incidence of Postpartum Depression. 2021 , 44, 117-122	2
188	Prognostic models for predicting relapse or recurrence of major depressive disorder in adults. 2021 , 5, CD013491	4
187	Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic. 2021 , 144, 230-237	0

186	Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials. 2021 , 144, 300-309	
185	A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder. 2021 , 13, e16689	0
184	Effects of body-oriented yoga: a RCT study for patients with major depressive disorder. 2021 , 271, 1217-1229	0
183	Stress-Related Dysfunction of Adult Hippocampal Neurogenesis-An Attempt for Understanding Resilience?. 2021 , 22,	6
182	Using implementation intentions to prevent relapse after remission from psychological treatment for depression: The SMART intervention. 2021 , 1-12	
181	Antidepressant Discontinuation: In Need of Scientific Evidence. 2021 , 41, 512-515	0
180	The Pursuit and Maintenance of Happiness. 2021 , 385, 1327-1328	1
179	Maintenance or Discontinuation of Antidepressants in Primary Care. 2021 , 385, 1257-1267	16
178	Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. 2021 , 20, 387-396	7
177	Polypharmazie in der Behandlung von Persönlichkeits- und Verhaltensstörungen. 2006 , 121-137	5
176	Life Course Perspectives on Social Factors and Mental Illness. 2007 , 191-218	25
175	Deprescribing and Its Application to Psychiatry. 2019 , 137-153	3
174	Green Engineering of Silver Nanoparticles to Combat Plant and Foodborne Pathogens: Potential Economic Impact and Food Quality. 2019 , 451-476	2
173	Antidepressants: Indications, Contraindications, Interactions, and Side Effects. 2020 , 1-38	2
172	Taking People as They Are: Evolutionary Psychopathology, Uncomplicated Depression, and Distinction between Normal and Disordered Sadness. 2017 , 37-72	2
171	Antidepressiva. 2012 , 589-628	0
170	Molecular Imaging of Depressive Disorders. 2014 , 93-172	6
169	Depressive Störungen. 2017 , 1711-1817	1

168	Unipolar depression. 2012 , 287-311	1
167	Konsiliar- und Liaisondienste für psychische Störungen. 2012 , 895-917	1
166	Affective instability predicts the course of depression in late middle-age and older adulthood. 2018 , 239, 72-78	9
165	Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. 2017 , 4, 547-553	27
164	Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence. 2018 , 86, 189-199	9
163	Bioethics. 2006 ,	129
162	Mental Maladies. 2006 , 165-189	1
161	Adequate Information, Competence, and Coercion. 2006 , 213-234	3
160	Paternalism and Its Justification. 2006 , 237-278	1
159	Low predictive power of clinical features for relapse prediction after antidepressant discontinuation in a naturalistic setting.	1
158	Opioid relapse prediction with GAN. 2019 ,	3
157	Improving Depression Outcome by Patient-Centered Medical Management. 2020 , 18, 244-254	1
156	Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. 2008 , 59, 1121-30	42
155	Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review. 2009 , 60, 157-74	39
154	One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials. 2020 , 34, 1074-1078	11
153	Depression and anxiety. 2005 , 135-203	2
152	[Relapse in depressive disorders--is there a need for maintenance psychotherapy?]. 2003 , 49, 377-90	7
151	[Evidence-based treatment of depression: what does the new S3- and national healthcare guideline Unipolar Depression really recommend?]. 2010 , 56, 334-42	4

150	The effects of cognitive therapy versus 'no intervention' for major depressive disorder. 2011 , 6, e28299	27
149	The effects of centralised and specialised intervention in the early course of severe unipolar depressive disorder: a randomised clinical trial. 2012 , 7, e32950	7
148	A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. 2012 , 7, e45515	21
147	Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study). 2013 , 8, e70588	27
146	A Psycho-Behavioral Perspective on Modelling Obsessive-Compulsive Disorder (OCD) in Animals: The Role of Context. 2018 , 25, 5662-5689	5
145	Medical Management of Obesity Associated with Mood Disorders. 2006 , 369-416	1
144	The pharmacological management of depression. 2005 , 7, 191-205	34
143	Towards achieving remission in the treatment of depression. 2008 , 10, 371-5	14
142	Major depression during interferon-alpha treatment: vulnerability and prevention. 2009 , 11, 417-25	46
141	Heading off depressive illness evolution and progression to treatment resistance. 2015 , 17, 105-9	11
140	Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. 2010 , 107, 700-8	43
139	The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study). 2015 , 19, 1-124	36
138	The role of patient experience and its influence on adherence to antidepressant treatment. 2013 , 51, 29-37	7
137	Association of suicide and antidepressant prescription rates in Japan, 1999-2003. 2007 , 68, 908-16	45
136	Use of the internet to assist in the treatment of depression and anxiety: a systematic review. 2010 , 12,	14
135	A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. 2011 , 13,	6
134	A review of antidepressant therapy in primary care: current practices and future directions. 2013 , 15,	20
133	Improving adherence to sertraline treatment: the effectiveness of a patient education intervention. 2006 , 8, 285-90	4

- 132 Evaluation of the central and peripheral effects of doxepin on carrageenan-induced inflammatory paw edema in rat. **2017**, 12, 337-345 4
- 131 Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder. **2016**, 13, 440-6 8
- 130 Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study. **2017**, 21, 62-67 5
- 129 The impact of shared decision-making on the treatment of anxiety and depressive disorders: systematic review. **2021**, 7, 1
- 128 Curso anual del primer episodio de depresi3n frente a episodios mltiples de depresi3n. Un estudio naturalista polaco. **2004**, 11, 485-490
- 127 Hoe moeten antidepressiva worden afgebouwd?. **2006**, 2820-2822
- 126 Langzeittherapie und Rezidivprophylaxe depressiver St3nungen. **2006**, 249-253
- 125 Particular Moral Rules and Special Duties. **2006**, 77-97
- 124 What Doctors Must Know about Medical Practice. **2006**, 191-210
- 123 Moral Disagreement. **2006**, 51-75
- 122 Introduction. **2006**, 3-19
- 121 Death. **2006**, 283-307 1
- 120 Euthanasia. **2006**, 309-343
- 119 Principlism. **2006**, 99-126
- 118 Morality. **2006**, 21-47 1
- 117 Malady. **2006**, 129-163
- 116 El programa APRAND: una intervenci3n para prevenir reca3das de los trastornos de ansiedad y depresivos. Primeros resultados de una intervenci3n m3dica de promoci3n de la salud en una poblaci3n de empleados. **2007**, 14, 119-128
- 115 Diagnosis and treatment of major depression 2007. **2007**, 11, 35-42 2

114 Antidepressants. **2008**, 595-619

113 Depressive Störungen. **2008**, 1401-1472

112 Polypharmazie in der Behandlung von Persönlichkeits- und Verhaltensstörungen. **2009**, 137-154

111 Konsiliar- und Liaisondienste für psychische Störungen 11 In memoriam Dr. phil. Dr. med. Rolf Saupe (1952-2007). **2009**, 1025-1050 1

110 Unipolare Depression [Pharmakotherapie und Psychotherapie (ICD-10 F3)]. **2009**, 131-169 1

109 Continuation and maintenance treatment. **2009**, 85-90

108 DEPRESSION AND BIPOLAR DISORDERS. **2009**, 787-795

107 Outcomes in the Treatment of Major Depressive Disorder. **2009**, 22-53

106 Continuation and maintenance treatment. **2011**, 85-90

105 Depressive Störungen. **2011**, 1575-1664

104 Unipolar depressive Störungen. **2012**, 961-991

103 Psychopharmakologie. **2012**, 91-130

102 Anxiety and Depression. **2012**, 1060-1077

101 Treatment of mood disorders. **2012**, 669-680

100 From science to practice. **2012**, 122-130

99 Biological Treatment of Mood Disorders. 143-172

98 Encyclopedia of Psychopharmacology. **2014**, 1-9

97 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91

- 96 Continuation and Maintenance Treatment. **2014**, 99-105
- 95 Psychopharmakologie. **2015**, 87-124
- 94 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96
- 93 Long-Term Treatment of Mood Disorders: Follow-Up of Acute Treatment Phase Studies Versus Continuation and Maintenance Phase Studies, and Enriched Versus Non-Enriched Designs. **2015**, 29-47
- 92 Pharmacological Management of Anxiety and Depression in Older People. **2016**, 93-113
- 91 Depressive Störungen. **2016**, 1-107
- 90 Praxis der pharmakologischen Erhaltungstherapie und Rezidivprophylaxe. **2017**, 241-255
- 89 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111
- 88 Störungsbild unipolare Depression. **2017**, 25-43
- 87 Major Depressive Disorder. **2017**,
- 86 Trends in pharmacotherapy of unipolar depression. **2017**, 18, 120-124
- 85 Kurz- und langfristige Wirksamkeit von Psychotherapie bei Depression im Vergleich zu medikamentöser Therapie. **2018**, 66, 19-29 3
- 84 Klinische Wirksamkeit der Schematherapie bei Depressionen. **2018**, 29, 42-52
- 83 Psychopharmakologie. **2019**, 75-104.e3
- 82 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 81 Absetzen von Antidepressiva. **2019**, 30, 27-31
- 80 Mood Stabilizers: Classification, Indications and Differential Indications. **2020**, 1-7
- 79 [Need for Prescription Suggestions for Long-term Inpatients in the Psychiatric Ward]. **2020**, 140, 1025-1033

78 Doctors' health & performance. **2020**, 860-879

77 Trauma. **2020**, 520-567

76 Ear, nose, and throat. **2020**, 384-431

75 Molecular Imaging of Depressive Disorders. **2021**, 85-207

0

74 Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study. **2022**, 296, 609-615

0

73 [Clinical and sociodemographic characteristics of patients with the first depressive episode and recurrent depression]. **2020**, 120, 33-39

0

72 The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse.

71 Langzeitbehandlung und Suizidprävention bei rezidivierenden unipolaren Depressionen. **2005**, 489-501

70 Antidepressiva. **2008**, 515-553

69 Affektive Störungen. **2008**, 873-909

68 Evidence-based medicine in managed care: a survey of current and emerging strategies. **2004**, 6, 56

2

67 Antidepressant use in older people: family physicians' knowledge, attitudes, and practices. **2005**, 51, 80-1

5

66 Safe use of SSRIs in young adults: how strong is evidence for new suicide warning?. **2007**, 6, nihpa81089

2

65 Depression in adults: drug and physical treatments. **2007**, 2007,

3

64 Depression in adults: drug and physical treatments. **2011**, 2011,

8

63 The relationship of antidepressant prescribing concentration to treatment duration and cost. **2012**, 15, 3-11

4

62 A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. **2014**, 11, 10-22


10

61 Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. **2021**, 21, 1-214

- 60 Interventions for preventing relapse or recurrence of major depressive disorder in adults in a primary care setting: a network meta-analysis. **2021**, 2021,
- 59 Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. **2021**, 25, 1-62 0
- 58 Factors associated with relapse and recurrence of major depressive disorder in patients starting mindfulness-based cognitive therapy. **2021**, 0
- 57 Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. **2021**, 24, 1299-1308
- 56 More treatment but no less depression: The treatment-prevalence paradox.. **2021**, 91, 102111 7
- 55 Emergency medicine. **2020**, 568-623
- 54 Pre-hospital emergency medicine. **2020**, 624-655
- 53 General practice. **2020**, 774-841
- 52 Obstetrics. **2020**, 1-103
- 51 Dermatology. **2020**, 432-461
- 50 Psychiatry. **2020**, 682-773 0
- 49 Eponymous syndromes. **2020**, 842-859
- 48 Paediatrics. **2020**, 178-319
- 47 Orthopaedics. **2020**, 462-519 1
- 46 Anaesthesia. **2020**, 656-681
- 45 Ophthalmology. **2020**, 320-383
- 44 Oxford Handbook of Clinical Specialties. **2020**, 2
- 43 Gynaecology. **2020**, 104-177

42	Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	1
41	Predicting relapse or recurrence of depression: systematic review of prognostic models.. <i>British Journal of Psychiatry</i> , 2022 , 1-11	5.4	0
40	A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for Depression.. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
39	Predictors of successful discontinuation of antipsychotics and antidepressants.. <i>Psychological Medicine</i> , 2021 , 1-11	6.9	
38	Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.. <i>Drug and Therapeutics Bulletin</i> , 2022 , 60, 7-12	0.9	2
37	Depression and Anxiety Disorders. 305-450		
36	A Systematic Review of Long-term Antidepressant Outcomes in Comorbid Depression and Type 2 Diabetes.		
35	Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. <i>BJ Psych Advances</i> , 1-15	0.8	1
34	Effectiveness of Pharmacotherapy for Depression after Adult Traumatic Brain Injury: an Umbrella Review. <i>Neuropsychology Review</i> ,	7.7	0
33	Low predictive power of clinical features for relapse prediction after antidepressant discontinuation in a naturalistic setting. <i>Scientific Reports</i> , 2022 , 12,	4.9	
32	Copyright Page. 2006 , iv-iv		
31	Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis. 2022 , 17, e0272200		
30	Preface. 2006 , v-x		0
29	EFFECT OF AGOMELATINE AND SERTRALINE ON PATIENTS WITH MAJOR DEPRESSIVE DISORDERS AND CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROLLED TRIAL. 6, e0127		0
28	Effectiveness of CBT and its modifications for prevention of relapse/recurrence in depression: A systematic review and meta-analysis of randomized controlled trials. 2022 , 319, 469-481		0
27	Depression: Third Wave Case Conceptualization. 2022 , 397-413		0
26	Pharmakotherapie: Erhaltungstherapie und Rezidivprophylaxe. 2023 , 177-188		0
25	Antidepressants: Indications, Contraindications, Interactions, and Side Effects. 2022 , 1135-1172		0

24	Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy. 2022 , 1173-1191	0
23	Mood Stabilizers: Classification, Indications and Differential Indications. 2022 , 1429-1435	0
22	Comparison on the clinical features in patients with or without treatment-resistant depression: A National Survey on Symptomatology of Depression report. 2023 , 319, 114972	2
21	Effect of Personality Traits on Sustained Remission Among Patients with Major Depression: A 12-Month Prospective Study. Volume 18, 2771-2781	0
20	Integrative medicine approaches to chronic depression: case studies of the recovery process with a three-step path to recovery and significant cure. 2022 ,	0
19	Transitions in depression: if, how, and when depressive symptoms return during and after discontinuing antidepressants.	1
18	Barriers and Facilitating Factors of Adherence to Antidepressant Treatments: An Exploratory Qualitative Study with Patients and Psychiatrists. 2022 , 19, 16788	0
17	A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder. 2023 , 331, 111634	0
16	Preface to 11th edition. 2020 , iv-iv	0
15	Symbols and abbreviations. 2020 , viii-x	0
14	A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder. 2023 , 447, 114431	0
13	Copyright Page. 2020 , ii-ii	0
12	Preface to 1st edition. 2020 ,	0
11	Updates and Amendments. 2020 ,	0
10	Drugs. 2020 ,	0
9	Dedication. 2020 , vi-vi	0
8	ˆ 2020 ,	0
7	A randomized controlled trial of surf and hike therapy for U.S. active duty service members with major depressive disorder. 2023 , 23,	0

- 6 Reference intervals *Baematology*. **2020**,
- 5 Reference intervals *Biochemistry*. **2020**,
- 4 Interventions to help patients withdraw from depression drugs: systematic review.
- 3 Psychiatric rehabilitation and cognitive deficit for treatment-resistant depression. **2023**,
- 2 Risk Ahead: Actigraphy-Based Early-Warning Signals of Increases in Depressive Symptoms During Antidepressant Discontinuation. 216770262211481
- 1  **2016**, 81-86